On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.
Prescribe Otezla 30 mg tablets for an appropriate patient
Request Starter Pack in section 4 of the START Form or from your Otezla Sales Representative
PA is required
SP coordinates co‑pay collection and direct mail shipment of medication to the patient
Submit PA form along with other required documentation to the insurer
PA is denied
SP coordinates co‑pay collection and direct mail shipment of medication to the patient
Appeal the denial by submitting the Letter of Medical Necessity and other required documentation to the insurer. Request this document on the Letter of Medical Necessity page, or contact OSP, 1-844-4OTEZLA (1-844-468-3952) 8 AM - 8 PM ET, Monday - Friday
Should appeals be denied
SP coordinates co‑pay collection and direct mail shipment of medication to the patient
SP coordinates co‑pay collection and direct mail shipment of medication to the patient
Refer patient to the OSP to determine eligibility for the Patient Assistance Program
Otezla® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Contraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Please click here for Full Prescribing Information.
Otezla® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Contraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Please click here for Full Prescribing Information.